Abstract
Apatinib (YN968D1) is a small-molecule tyrosine kinase inhibitor(TKI)which can inhibit the activity of vascular endothelial growth factor receptor-2 (VEGFR-2). It has been reported that apatinib has anti-tumour effect of inhibiting proliferation and inducing apoptosis of a variety of solid tumour cells, whereas its effect on vascular smooth muscle cells (VSMC) remains unclear. This study investigated the effect of apatinib on phenotypic switching of arterial smooth muscle cells in vascular remodelling. Compared to the vehicle groups, mice that were performed carotid artery ligation injury and treated with apatinib produced a reduction in abnormal neointimal area. For in vitro experiment, apatinib administration inhibited VSMC proliferation, migration and reversed VSMC dedifferentiation with the stimulation of platelet-derived growth factor type BB (PDGF-BB).In terms of mechanism, with the preincubation of apatinib, the activations of PDGF receptor-β (PDGFR-β) and phosphoinositide-specific phospholipase C-γ1 (PLC-γ1) induced by PDGF-BB were inhibited in VSMCs. With the preincubation of apatinib, the phosphorylation of PDGFR-β, extracellular signal-related kinases (ERK1/2) and Jun amino-terminal kinases (JNK) induced by PDGF-BB w...Continue Reading
References
Sep 6, 1991·Science·G A FernsR Ross
May 3, 1991·Cell·H K KimS G Rhee
Apr 1, 1996·The International Journal of Biochemistry & Cell Biology·L Claesson-Welsh
Sep 18, 1998·Biochimica Et Biophysica Acta·C H HeldinL Rönnstrand
Jul 27, 1999·The Journal of Biological Chemistry·H Nagase, J F Woessner
Jun 23, 2004·Cytokine & Growth Factor Reviews·Linda FredrikssonUlf Eriksson
Jul 23, 2004·Physiological Reviews·Gary K OwensBrian R Wamhoff
Jan 13, 2009·BMC Genomics·Stefano CagninGerolamo Lanfranchi
Nov 3, 2010·European Journal of Pharmacology·Jung-Jin LeeYeo-Pyo Yun
Jan 22, 2011·Cardiovascular Research·Kun YuJin-kun Wen
Mar 30, 2011·Cancer Science·Shu TianLiguang Lou
Oct 16, 2012·Molecular and Cellular Biochemistry·Lihua ZhuHong Jiang
Jan 18, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·So IshiiShiro Minami
Aug 1, 2014·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jeonghan Kim, Jesang Ko
Nov 26, 2014·Expert Opinion on Pharmacotherapy·Ruixuan Geng, Jin Li
Jun 3, 2015·Biochemical and Biophysical Research Communications·Jung Min HaSun Sik Bae
Jun 23, 2015·Journal of Receptor and Signal Transduction Research·Yu SunHua-Fu Zhou
Jan 26, 2016·Cancer Letters·Sui PengMing Kuang
Jan 25, 2017·Expert Review of Cardiovascular Therapy·Damianos G KokkinidisEhrin J Armstrong
Aug 24, 2017·British Journal of Pharmacology·Hyun-Soo ParkChang-Seon Myung
Aug 25, 2017·Cell Death & Disease·Kuisheng LiuWei Guo
Jan 27, 2018·Cardiovascular Research·Kerry WadeySarah George
Apr 14, 2018·Journal of the American College of Cardiology·Juan TorradoLuis A Guzmán
Oct 12, 2018·Cell Death & Disease·Haoran FengWeihua Qiu
Nov 8, 2018·BMC Gastroenterology·Manping HuangSainan Zeng
Feb 14, 2019·Cancer Immunology Research·Sha ZhaoFred R Hirsch
Mar 15, 2019·Nature Communications·Cheng WangKai Huang